Watson Launches Generic Biaxin(R) XL( CORONA Calif. Jan. 3 /- WatsonPha...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Watson Launches Generic Biaxin(R) XL
Date:1/3/2008
CORONA, Calif., Jan. 3 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today it has launched Clarithromycin Extended-Release Tablets, USP in the 500 mg strength. Watson's Clarithromycin Extended-Release product is the generic equivalent to Abbott's Biaxin(R) XL, which is indicated to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. For the 12-months ending September 2007, Biaxin(R) XL and its generic equivalents had total U.S. sales of approximately $200 million, according to IMS Health data.
The U.S. Food and Drug Administration granted final approval of Watson's Abbreviated New Drug Application (ANDA) for Clarithromycin Extended-Release on June 24, 2004. Patent infringement litigation related to Watson's ANDA was dismissed with prejudice on July 12, 2007.
About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.
For press releases and other company information, visit Watson Pharmaceuticals' Web site at http://www.watsonpharm.com.
Forward-Looking Statement
Any statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements that
reflect Watson's current perspective of existing trends and information as
o
'/>"/>
| SOURCE Watson Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
2. APIC Launches Targeting Zero Initiative to Eradicate C. Difficile and Infections Deemed Preventable By CMS
3. Cepheid Launches New GeneXpert(R) Tests in Europe for Simultaneous, Rapid Detection of Staphylococcus Aureus and Methicillin Resistant Staphylococcus Aureus
4. PositiveFriends.com Launches STD Social Networking Site Balancing Dating with Online Support Features
5. Seal Shield Launches Worlds First Antibacterial, Dishwasher Safe Keyboard and Mouse for Infection Control
6. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
7. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
8. Premier Micronutrient Launches Supplement for Hearing Health
9. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
10. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
11. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
Post Your Comments:
(Date:11/26/2008)...HESTER, Minn., Nov. 26 ...rd are at significantly increased risk of developi... findings of a Mayo Clinic study published this m...merican Academy of Pediatrics. , , The retr...7 patients with strabismus (misaligned eyes) and c...
(Date:11/26/2008)...dy Expanded to 406 Subjects , , FRANKLIN, M...s Inc. (OTC Bulletin Board: PLCSF) announced today...Food and Drug Administration (FDA) for its U.S. pi...any,s RenalGuard System(TM) and associated therap...y (CIN). , , The FDA also approved PLC,s re...
(Date:11/25/2008)...ISVILLE, Ky., Nov. 25 K...urgeons performed the fifth U.S. hand transplant o... at Louisville,s Jewish Hospital Hand Care Center ...began around noon and was completed shortly after ... http://www.newscom.com/cgi-bin/prnh/20081125/DC4...
(Date:11/25/2008)...TH SAN FRANCISCO, Calif., Nov. 25 ...velopment of novel therapeutics that target,prote...iseases, today,announced that data from two ongoi...iple myeloma will be presented at the upcoming 50t...ology (ASH). Carfilzomib is the first in a new cl...
Breaking Medicine Technology:Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 2Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center 3Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 1Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 2Leading Worldwide Cause of Cardiovascular Disease May Be Modified by Diet 23346 3Rocker Joel Madden Named Newest UNICEF Goodwill Ambassador 23343 1Rocker Joel Madden Named Newest UNICEF Goodwill Ambassador 23343 2Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference 23340 1Cyberonics to Present at Collins Stewart Fourth Annual Growth Conference 23340 2Physicians Practice Promotes Key Executives 23337 1Physicians Practice Promotes Key Executives 23337 2[0] Eye Divergence in Children Triples Risk of Mental Illness[0] PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.[1] Kleinert Kutz Hand Surgeons Perform Fifth U.S. Hand Transplant in Record Time at Jewish Hospital Hand Care Center[1] Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology
...t Randomized, Placebo-controlled Trial,Ever Conduc...linical Oncology, CHICAGO, June 04, 2007 /PRNewswi...ed, placebo-controlled clinical trial ever,conduct...L) showed,that ONTAK was more than twice as effect... patients with CTCL. [Abstract number 8026],The pr...
...With Follicular Lymphoma Reported,Today at ASCO An...ire/ -- GlaxoSmithKline plc,announced today long-t...e one-week course of frontline treatment with the ...ine I-131 Tositumomab) in,76 patients with newly d...a (NHL). This regimen was found to induce durable ...
Other Medicine Technology:Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 2Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 3Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 4Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 5Ontak (denileukin diftitox) Achieves 49.1% Overall Response Rate in,Phase III Trial of Cutaneous T-Cell Lymphoma (CTCL) 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 28-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 38-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 48-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 58-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 68-Year Long-term Data Demonstrate Prolonged Overall Survival and,Length of Disease Remission with Bexxar 7(Date:12/2/2008)...orld Wide Dictation Service, one of the premier le...ption, and legal dictation transcription, has joi... non-profit organization geared to the betterment ...amilies throughout Lower Westchester County, New Y...) December 3, 2008 -- World Wide Dictation Service...
(Date:12/2/2008)...oes your over-the-phone interpretation vendor cont...completed the call? , Was...orld of over-the-phone interpretation (OPI), every...er one minute can add up over the course of a bill...ganization employs an over-the-phone interpretatio...
(Date:12/2/2008)...rion Health announces that the SouthEast Alaska Re...a, has selected the Rhapsody™ Integration En...d, radiology, pharmacy, laboratory and business pr...to extend connectivity to statewide systems such a...ry) and AKAIMS (an MIS and clinical documentation ...
(Date:12/1/2008)... Including a patient,s ...meticulous reading from the radiologist interpreti...thetic approach, according to a study presented to...ety of North America (RSNA). , , "Our stud...ing and not as an anonymous case study," said lead...
Breaking Medicine News(10 mins):Health News:World Wide Dictation Service Teams up with TMATT for Local Thanksgiving Community Dinner 2Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 2Health News:Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Patient Photos Spur Radiologist Empathy and Eye for Detail 2Health News:Patient Photos Spur Radiologist Empathy and Eye for Detail 3[0] World Wide Dictation Service Teams up with TMATT for Local Thanksgiving Community Dinner [0] Be Aware: Over-the-Phone Interpretation Billing Methods Vary Widely[0] SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring[0] Patient Photos Spur Radiologist Empathy and Eye for Detail
...ntified particular genes that are most prone to be...alled DNA promoter hypermethylation. Hypermethyla... normal cell development, to generate proteins tha...ehavior, or unregulated cell growth. So far, dat...
... between an extreme form of sleep disorder, REM Be...tia or parkinsonism. Patients with RBD have a hi...tia, Parkinsons disease or multiple system atrophy...pear to stem from a similar neurodegenerative orig...
...iasts and experts in the capital are strongly oppo...ng to recent reports of yet another application fi...l that the very idea of patenting knowledge like y..."Patenting of any kind is highly unjustified and w...
...age for mental illness does not increase usage and...who have children with mental illness, a Yale Scho... Services Research. Prior research has left polic...te parity laws will neither break the bank nor con...
Other Medicine News:Health News:Researchers Have Identified Cancer Promoter Genes 2Health News:Researchers Find Link Between Sleep Disorder and Dementia 2Health News:Yoga Enthusiasts Oppose Patenting Yoga Overseas 2Health News:Coverage for Childrens Mental Illness Reduces Out-of-Pocket Spending 2Eyeglass Loupe 3x-5x made with precision optical glass. Ideal for any detail work.
Near PT test card/child recog/ playing cards 5 1/2" X 8".
Near point card/newspaper 8 to 48 point type 5 1/2" X 8".
Near point card 4 1/2 to 24 PT 5 1/2" x 8".
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |